Patients with metastatic melanoma who undergo surgery to remove lesions that have spread into the abdomen live more than twice as long as those treated with drug therapy alone, according to novel research presented at the American College of Surgeons Clinical Congress 2015.
MRV Research
Metastasis switch discovered in melanoma
Melanoma, as with most other cancers, is life-threatening when metastasis occurs. In a new investigation focusing on decisive epigenetic changes that may trigger or take place in metastasis, an international team led by Manel Esteller, a Spanish epigeneticist, compared the DNA methylation patterns of primary and metastatic melanoma cells.
Amgen’s Imlygic recommended for European approval
A potential first-in-class oncolytic immunotherapy, Imlygic is administered via intralesional injection and designed to cause the death of tumour cells.
Enhanced Immune Response Seen With Radiation/Ipilimumab Combo in Melanoma
Proinflammatory cytokines were elevated in patients with melanoma undergoing the combination treatment of radiation therapy and the systemic anti–CTLA-4 immunotherapy, ipilimumab, according to findings presented by Susan Hiniker, MD, an instructor in radiation oncology at the Stanford University School of Medicine, during the 2015 American Society for Radiation Oncology (ASTRO) Annual Meeting. The findings suggest a relationship between elevated CD8 activated T cells among responders (eg, MCP-1, MIG, and IP-10).